Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluticasone Propionate

FDA-approved product (ointment, topical), marketed as Armonair Digihaler, Armonair Respiclick, Cutivate and 9 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fluticasone Propionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Atopic eczema
  • Chronic bronchitis
  • Chronic obstructive pulmonary disease
  • Emphysema
  • Nasal Cavity Polyp
  • Nasal congestion
  • Nasal polyposis
  • Seasonal allergic rhinitis
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, potent (group iii); Corticosteroids; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluticasone Propionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluticasone Propionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of the Adjunctive Effects of Moxibustion in the Treatment of Cold-Syndrome Allergic Rhinitis

    NCT07537439 · start 2026-03-01

    Registered record
    Registry ID
    NCT07537439
    Conditions
    Allergic Rhinitis (AR)
    Interventions
    Mild moxibustion; Fluticasone propionate 100 mcg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2026-03-01
    Completion
    2026-10-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis (AR)
    InterventionMild moxibustion; Fluticasone propionate 100 mcg
    PhaseNot applicable
    Registry statusActive not recruiting

  • Role of Lung Function for Exercise Capacity in Well-trained Individuals

    NCT06077019 · start 2023-10-03

    Registered record
    Registry ID
    NCT06077019
    Conditions
    Exercise Performance
    Interventions
    Vilanterol and Fluticasone Furoate; Indacaterol and Mometasone Furoate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-10-03
    Completion
    2026-12-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExercise Performance
    InterventionVilanterol and Fluticasone Furoate; Indacaterol and Mometasone Furoate; Placebo
    PhaseNot applicable
    Registry statusRecruiting

  • Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults

    NCT04265105 · start 2021-12-22

    Registered record
    Registry ID
    NCT04265105
    Conditions
    Asthma
    Interventions
    fluticasone-vilanterol; Standard Preparation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-12-22
    Completion
    2023-01-18
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    Interventionfluticasone-vilanterol; Standard Preparation
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions

    NCT05021887 · start 2021-08-13

    Registered record
    Registry ID
    NCT05021887
    Conditions
    Asthma; Bioequivalence
    Interventions
    Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals; FLOVENT DISKUS
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2021-08-13
    Completion
    2021-11-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma; Bioequivalence
    InterventionFluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals; FLOVENT DISKUS
    PhasePhase 1
    Registry statusUnknown

  • Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients

    NCT04271839 · start 2020-06-11

    Registered record
    Registry ID
    NCT04271839
    Conditions
    Persistent Asthma
    Interventions
    fluticasone/formoterol k-haler (medium strength); Standard of care (ICs/LABA high strength)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2020-06-11
    Completion
    2021-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPersistent Asthma
    Interventionfluticasone/formoterol k-haler (medium strength); Standard of care (ICs/LABA high strength)
    PhasePhase 4
    Registry statusWithdrawn

  • Comparison of Three Modalities to Assess Clinical Competence of Medical Students

    NCT03884114 · start 2019-03-20

    Registered record
    Registry ID
    NCT03884114
    Conditions
    Educational Problems
    Interventions
    High-fidelity simulation; Simulation game; Multiple choice questionnaire
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-03-20
    Completion
    2019-07-06
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEducational Problems
    InterventionHigh-fidelity simulation; Simulation game; Multiple choice questionnaire
    PhaseNot applicable
    Registry statusCompleted

  • Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics

    NCT03002389 · start 2017-11-05

    Registered record
    Registry ID
    NCT03002389
    Conditions
    Chronic Obstructive Pulmonary Disease
    Interventions
    Anoro Ellipta; Arnuity Ellipta
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-11-05
    Completion
    2028-01-31
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease
    InterventionAnoro Ellipta; Arnuity Ellipta
    PhasePhase 2
    Registry statusActive not recruiting

  • Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

    NCT03219866 · start 2017-10-03

    Registered record
    Registry ID
    NCT03219866
    Conditions
    COPD; COPD Exacerbation
    Interventions
    Nebulizers; Dry Powder Inhaler; Brovana; Pulmicort; Atrovent; Advair Diskus; Spiriva HandiHaler
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-10-03
    Completion
    2020-04-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD; COPD Exacerbation
    InterventionNebulizers; Dry Powder Inhaler; Brovana; Pulmicort +3 more
    PhasePhase 4
    Registry statusTerminated

  • The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

    NCT03240575 · start 2017-08-14

    Registered record
    Registry ID
    NCT03240575
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    Tiotropium; Olodaterol; Fluticasone propionate; Salmeterol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-08-14
    Completion
    2019-05-06
    Enrolment
    302

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    InterventionTiotropium; Olodaterol; Fluticasone propionate; Salmeterol
    PhasePhase 4
    Registry statusCompleted

  • Asthma Research in Children and Adolescents

    NCT04480242 · start 2017-07-26

    Registered record
    Registry ID
    NCT04480242
    Conditions
    Persistent Asthma; Asthma in Children; Asthma Exacerbation
    Interventions
    Inhaled Corticosteroids (ICs); Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA); Other treatments; Inhaler device; Regularly monitoring of the Inhalation technique through mobile app
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2017-07-26
    Completion
    2030-12-31
    Enrolment
    525

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPersistent Asthma; Asthma in Children; Asthma Exacerbation
    InterventionInhaled Corticosteroids (ICs); Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA); Other treatments; Inhaler device +1 more
    PhaseNot recorded
    Registry statusActive not recruiting

  • A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma

    NCT03184987 · start 2017-06-22

    Registered record
    Registry ID
    NCT03184987
    Conditions
    Asthma
    Interventions
    FF/UMEC/VI 100/62.5/25 mcg; FF/UMEC/VI 200/62.5/25 mcg; Salbutamol; ACQ-7
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-06-22
    Completion
    2019-06-25
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFF/UMEC/VI 100/62.5/25 mcg; FF/UMEC/VI 200/62.5/25 mcg; Salbutamol; ACQ-7
    PhasePhase 3
    Registry statusCompleted

  • Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma

    NCT03461627 · start 2017-04-01

    Registered record
    Registry ID
    NCT03461627
    Conditions
    Asthma
    Interventions
    Salmeterol Xinafoate and Fluticasone Propinate Powder; Seretide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-04-01
    Completion
    2018-10-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionSalmeterol Xinafoate and Fluticasone Propinate Powder; Seretide
    PhasePhase 3
    Registry statusUnknown

  • Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

    NCT02573870 · start 2015-12-01

    Registered record
    Registry ID
    NCT02573870
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    Batefenterol + Fluticasone Furoate; Placebo; Albuterol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-12-01
    Completion
    2016-07-05
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    InterventionBatefenterol + Fluticasone Furoate; Placebo; Albuterol
    PhasePhase 2
    Registry statusCompleted

  • Modulation of Steroid Immunosuppression by Alveolar Efferocytosis

    NCT03034642 · start 2015-10-01

    Registered record
    Registry ID
    NCT03034642
    Conditions
    Pulmonary Disease, Chronic Obstructive; Pneumonia, Bacterial
    Interventions
    Bronchoscopy with bilateral bronchoalveolar lavages
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-10-01
    Completion
    2021-12-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive; Pneumonia, Bacterial
    InterventionBronchoscopy with bilateral bronchoalveolar lavages
    PhaseNot applicable
    Registry statusCompleted

  • Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis

    NCT02019758 · start 2015-01-01

    Registered record
    Registry ID
    NCT02019758
    Conditions
    Eosinophilic Esophagitis
    Interventions
    Oral Viscous Budesonide; Fluticasone MDI; Placebo slurry; Placebo inhaler
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-01-01
    Completion
    2019-04
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEosinophilic Esophagitis
    InterventionOral Viscous Budesonide; Fluticasone MDI; Placebo slurry; Placebo inhaler
    PhasePhase 4
    Registry statusCompleted